TESARO (TSRO) Misses Q1 EPS by 31c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
TESARO Announces First-Quarter 2017 Operating Results
May 9, 2017 4:06 PM EDTZEJULA approved by U.S. FDA for the maintenance treatment of women with recurrent ovarian cancer, regardless of BRCA or biomarker status; commercial launch underwayZEJULA added to the NCCN Clinical Practice Guidelines in Oncology Expanded development program for niraparib in ovarian, lung and breast cancers to begin 2H 2017VARUBY® approved in Europe and launches to begin late 2Q 2017VARUBI® IV NDA re-submitted to FDA; approval anticipated late 2Q 2017 TSR-042 clinical program now open to enroll patients with MSI-H endometrial... More
